Covid-19 drug enters human testing phase

Updated 22 May 2020

Email

The drug, named TR-C 19, can neutralise the virus under laboratory conditions. — AFP/File
The drug, named TR-C 19, can neutralise the virus under laboratory conditions. — AFP/File

LAHORE: The de Khon Global and its partners in the Netherlands and Turkey have reportedly reached the human testing phase in the development of a drug to treat Covid-19.

According to a press release, the breakthrough has come from the VSY Biotechnology B.V., based in Netherlands, one of the strategic partner company of de Khon Global. The drug, named TR-C 19, can neutralise the virus under laboratory conditions and it is now at authority approval stage for usage on voluntary Covid-19 patients and clinical trials.

Dr Faisal Q Khokhar, the executive director of Remington Pharmaceuticals, stated: “We are committed to making the impossible possible. We are facing this public health challenge head on by collaborating with our industry partners in Europe and academic institutions to develop potential novel approaches to prevent and treat Covid-19. We are leaving no stone unturned as we explore every option to help provide society with a treatment or cure.”

The statement said science and the global resources were being applied to battle the virus and the company and its partners were bringing the cutting edge research to life in the form of the life-saving drug, TR-C19, that would cure Covid-19.

The de Khon Global is a part of Remington Pharmaceuticals & KOBEC Health Sciences.

Published in Dawn, May 22nd, 2020